A novel combination therapy pairing a DNA-synthesis inhibitor with a targeted radiopharmaceutical may improve outcomes for patients with advanced neuroendocrine tumors, according to new clinical trial ...
A novel combination therapy pairing a DNA-synthesis inhibitor with a targeted radiopharmaceutical may improve outcomes for patients with advanced neuroendocrine tumors, according to new clinical trial ...
The cancer drugs called PARP inhibitors have a puzzling reputation: even though they are treatment mainstays for multiple forms of cancer, they can damage cancer-killing T cells and disrupt the ...
Aman Chauhan, M.D., leader of the Neuroendocrine Tumor Program at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, and associate professor of medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results